Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
9.28
-5.66 (-37.88%)
At close: Aug 1, 2025, 4:00 PM
9.30
+0.02 (0.22%)
After-hours: Aug 1, 2025, 5:18 PM EDT

Silexion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2013FY 2012
Period Ending
Dec '24 Dec '23 Dec '13 Dec '12
Selling, General & Admin
6.760.970.240.17
Research & Development
5.823.711.120.79
Operating Expenses
12.574.681.360.95
Operating Income
-12.57-4.68-1.36-0.95
Interest Expense
-0.03--0-0
Interest & Investment Income
0.030.1500.01
Currency Exchange Gain (Loss)
-0.25-0.4500.01
Other Non Operating Income (Expenses)
-3.69-0.1--
Pretax Income
-16.51-5.08-1.36-0.94
Income Tax Expense
0.010.03--
Earnings From Continuing Operations
-16.52-5.11-1.36-0.94
Minority Interest in Earnings
0.080.17--
Net Income
-16.44-4.94-1.36-0.94
Net Income to Common
-16.44-4.94-1.36-0.94
Shares Outstanding (Basic)
0---
Shares Outstanding (Diluted)
0---
EPS (Basic)
-395.36---
EPS (Diluted)
-395.36---
Free Cash Flow
-8.42-4.54-0.8-0.91
Free Cash Flow Per Share
-202.40---
EBITDA
-12.55-4.64-1.36-0.95
D&A For EBITDA
0.030.0500
EBIT
-12.57-4.68-1.36-0.95
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q